The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
https://twitter.com/Phoenix_Copper/status/1473548865773129730
EQTEC has released an update on two strategic partnerships. The first is a new framework agreement with H2 Energy Solutions, a German hydrogen project development and principal investment company, to jointly define and pursue waste-to-hydrogen projects, particularly in Germany and Turkey. Any projects formally pursued would be subject to further commercial terms, and there are already two opportunities in Germany that have been identified by the two companies.
The H2 Energy collaboration follows the potential addition of a hydrogen element to EQTEC’s Deeside project in the UK, and a collaboration agreement with Wood for joint development of hydrogen production solutions using syngas (as produced by EQTEC’s gasification technology). As such, in our view today’s news represents further augmentation of the hydrogen leg of EQTEC’s business, while also continuing to demonstrate the versatility of the company’s gasification technology.
The second is a deepening of the existing strategic partnership with MetalNRG, announced earlier this year. EQTEC has already purchased £500k of MetalNRG shares (MetalNRG is itself UK listed), and today’s update reports this partnership being augmented via a £300k share swap. Overall, this will leave EQTEC holding 14.1% of MetalNRG. MetalNRG is a natural resources investment company in the process of diversifying its portfolio via biomass investments, and is already an investment partner in EQTEC’s Italia MDC biomass-to-energy project. This augmentation of the existing agreement should help further cement the partnership between the two companies, potentially assisting with funding for future EQTEC biomass projects, in our view.
No change to forecasts; our DCF-based valuation remains at 4.9p, and we have a Buy recommendation.
Mol42.
Yes. Maybe you have some relevant points there but - and it's a big but - the board has been beefed up recently and got some real talent and experience on board now. We have to wait awhile to see what difference they will make.
I remain hopeful.
KSH - Absolutely.
It's not just Rene though. I have 3 pharma related stocks and all tell the same story - DNL, DDDD & Rene.
All (I believe) grossly undervalued and I can't for the life of me, understand why.
This is great news this morning. Should set the price on fire a wee bit I hope.
Porky - Respect :-)
Staylong - Sounds like you have a fetish about Porky.
Dr Anomaly & JaiBabaSwami are trying to lump Eqt & Phe together as a great investment. Don't be fooled. They are 2 entirely different structures. Eqt has working plants. Phe has an experimental "thing" that works but cloaked in secrecy.
Eqt has a great BoD. Phe had Tim Yeo. A non-exec director (Kirsty Gogan) has quit - why ??
Share structure of Eqt is transparent. Phe has the White family pulling the strings.
Eqt about to declare a profit. Phe ????
All MHO but WTFDIK
aandi:
The major difference is the BoD.
What damage has Tim Yeo done/left at PHE which has yet to be discovered???
Our guys are miles in front both professionally and (can I say) honesty.
I was in PHE and stopped out (took my losses and re-invested in PXC). There are real problems under the surfacein PHE IMHO.
BWTFDIK.
Ready to fly
Phoenix Copper’s another cheap UK share that’s caught my attention recently. It’s not just due to the release of impressive survey results at its Red Star project in Idaho this week. The miner has discovered three new anomalies that it says “are significantly greater” than the discovery outcrop drilled in recent years.
It’s also not just because its American Depositary Receipts have received approval to trade over the counter in New York, giving it the opportunity to attract new investors.
I’m thinking of buying Phoenix Copper as clean energy investment and soaring electric vehicle demand should turbocharge copper consumption. Goldman Sachs thinks global copper off-take could soar 600% between now and 2030.
Buying mining shares can be risky business as cost overruns and production problems can hit profits hard. Still, I believe this company’s risk/reward profile is extremely attractive.
Thanks to Stig on the "other" site
htTps://www.4dpharmaplc.com/application/files/5016/3490/0344/4D_pharma_LBPS_DDDD_Corporate_deck_Oct_2021.pdf
That's a good read Balerno1.
Not as much value added for the Exosomes as I thought there would be - but early days.
Very positive.